Compare Ryanair Holdings plc (RYAAY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs TG Therapeutics Inc — how do they compare? Ryanair Holdings plc trades at $58.99 (market cap $29.31B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Ryanair Holdings plc is far larger — about 3.5× TG Therapeutics Inc's market cap, and Ryanair Holdings plc pays a 1.68% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RYAAY | TGTX | |
|---|---|---|
Market Cap | $29.31B | $8.26B |
Sector | Industrials | Health |
52-Week High | $73.82 | $59.06 |
52-Week Low | $53.24 | $26.39 |
Enterprise Value | $26.33B | $8.50B |
Dividend Yield | 1.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
